Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"translational oncology"”.

  1. LOCO-REGIONALLY TARGETING INTERLEUKIN-13 RECEPTOR ALPHA-2 AND MAXIMIZING THERAPEUTIC ACCESS TO GLIOBLASTOMAS USING BIOMARKER DIRECTED ALPHA PARTICLES

    … diving GBM stem-like cells (GSCs) (Nguyen et al, Translational Oncology 2011). Targeting such a GBM restricted biomarker, especially one that is also expressed by GSCs to deliver cytotoxic therapeutics and diagnostic agents could potentially lead to early diagnosis and result in an increase in …

    wfu Repository record for LOCO-REGIONALLY TARGETING INTERLEUKIN-13 RECEPTOR ALPHA-2 AND MAXIMIZING THERAPEUTIC ACCESS TO GLIOBLASTOMAS USING BIOMARKER DIRECTED ALPHA PARTICLES (opens in a new tab)

  2. Development of a canine model to evaluate CAR-T cell subsets

    … a rapidly expanding therapeutic modality in the oncology clinic. Immunotherapy with chimeric antigen receptor (CAR) T cells has demonstrated success in human blood cancers, although relapse occurs in ~50% of patients. In the context of solid tumors, CAR-T cells show only transient effects. As a …

    colostate Repository record for Development of a canine model to evaluate CAR-T cell subsets (opens in a new tab)

  3. Unraveling Host-Gut Microbiota Dialogue and Its Impact On Response to Immune Checkpoint Blockade

    <p>Cancer is a disease with only one degree of separation, affecting one in two men and one in three women in their lifetimes; accounting for 1 of every 6 deaths. While cancer mortality rates continue to improve, incidence rates are expected to rise and shift through 2050 due to epidemiological and …

    uthsc Repository record for Unraveling Host-Gut Microbiota Dialogue and Its Impact On Response to Immune Checkpoint Blockade (opens in a new tab)

  4. A pathways-based approach identifying determinants of drug resistance in oesophageal adenocarcinoma

    Introduction: <br/>Five-year survival rates for oesophageal adenocarcinoma (OAC) remain poor at approximately 15%. The development of drug-resistance limits the effectiveness of current chemotherapies, with less than 20% of patients experiencing complete pathological response, so the discovery of …

    qu-belfast Repository record for A pathways-based approach identifying determinants of drug resistance in oesophageal adenocarcinoma (opens in a new tab)